Results 1 to 10 of about 1,680 (126)

Augmented emicizumab-driven coagulation potential in hemophilia A state by in vitro and in vivo supplementation of combined factors IX and X [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Persons with hemophilia A (HA) and inhibitors undergoing emicizumab prophylaxis require bypassing agents when breakthrough bleeding occurs.
Mitsumasa Osuna, Yuto Nakajima, Eisuke Takami, Hirotoshi Nakano, Keiji Nogami   +4 more
doaj   +2 more sources

Emicizumab in the treatment of acquired hemophilia A: A Two-Center experience [PDF]

Annals of Hematology
Emicizumab is a FVIII mimetic antibody used in the treatment of inherited hemophilia A that could potentially be used in acquired hemophilia A (AHA) to achieve hemostasis and shorten hospital stay while reducing bypass therapies. We report on 12 cases of
Malcolm Su, Sean Yates, Melissa Sanchez, Yu-Min Shen   +3 more
doaj   +2 more sources

Anti-emicizumab antibodies and their relevance in clinical practice [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Emicizumab is licensed for treatment of people with hemophilia A (HA) of all ages, with and without factor (F)VIII inhibitors. It is well tolerated, and most of the treatment-related adverse events are of mild intensity and transient.
Carla Valsecchi, Lucia Schiavone, Sara Arcudi, Adriana Torri, Cristina Novembrino, Flora Peyvandi   +5 more
doaj   +2 more sources

Importance of Inhibitor Surveillance During Emicizumab Prophylaxis in Young Children With Hemophilia: An Illustrative Case Series [PDF]

Case Reports in Hematology
Hemophilia is an X-linked inherited bleeding disorder associated with bleeding, which starts in infancy. The age of initiation of prophylaxis with clotting factor concentrate is limited by the intravenous mode of administration. Emicizumab, a Factor VIII
Kelly A. Bush, Marc Durocher, Jacqueline Limjoco, Courtney D. Thornburg   +3 more
doaj   +2 more sources

NXT007 enhances in vitro coagulation potential in the coexistence of emicizumab in hemophilia A through distinct complex formation [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: NXT007 is a factor (F)VIIIa-mimetic bispecific antibody (BsAb) for hemophilia A (HA), engineered from emicizumab. It is designed to achieve non-hemophiliac levels of plasma coagulation potential and is currently under clinical development. In
Kazuki Yamaguchi, Kenta Haraya, Hikaru Koga, Kei Nishimura, Keito Inaba, Masaru Muraoka, Atsushi Muto, Takehisa Kitazawa   +7 more
doaj   +2 more sources

Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab

BMC Pediatrics, 2022
Purpose Real-world data and study data regarding therapy with Emicizumab in pediatric cohorts with haemophilia A is scarce. Especially, data on previously untreated pediatric patients (PUPs) and minimally treated patients (MTPs) are missing.
Hannah Glonnegger, Felicia Andresen, Friedrich Kapp, Stefano Malvestiti, Martin Büchsel, Barbara Zieger   +5 more
doaj   +4 more sources

AOZORA study: 3-year interim analysis of safety and joint health in pediatric people with hemophilia A receiving emicizumab prophylaxis [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Recurrent joint bleeding in people with hemophilia A (PwHA) can cause hemophilic arthropathy, resulting in limited movement and chronic pain.
Midori Shima, Hideyuki Takedani, Kaoru Kitsukawa, Masashi Taki, Akira Ishiguro, Chiai Nagae, Azusa Nagao, Daisuke Nosaka, Yui Kyogoku, Hiroki Oki, Keisuke Iwasaki, Keiji Nogami   +11 more
doaj   +2 more sources

Emicizumab, the factor VIII mimetic bispecific monoclonal antibody: effects on thrombin generation and thromboelastometry [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Emicizumab is used for prophylaxis of patients with hemophilia A. Because it is used at a fixed dose that is not based on laboratory testing, evaluation of its activity is occasionally needed.
Armando Tripodi, Marigrazia Clerici, Erica Scalambrino, Sara Arcudi, Roberta Gualtierotti, Cristina Novembrino, Flora Peyvandi   +6 more
doaj   +2 more sources

Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis [PDF]

Blood Advances
: Intracranial hemorrhage (ICH) and resulting neurologic disability are severe complications for a subset of infants with severe hemophilia A (HA). Although prophylactic factor replacement reduces bleeding risk, it is typically delayed until after age 1 ...
Samira Glaeser-Khan, Satoko Ito, Manraj Sra, Rhys Richmond, Robert D. Bona, Harlan M. Krumholz, Stacy E. Croteau, Adam Cuker, George Goshua   +8 more
doaj   +2 more sources

Factor VIII in vitro bioequivalence of denecimig (Mim8) hemostatic effect by thrombin generation assays [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Denecimig (Mim8, Novo Nordisk A/S) is a next-generation bispecific antibody designed to mimic activated factor (F)VIII and restore hemostasis in persons with hemophilia A.
Jacob Lund, Mirella Ezban, Kasper Jensen, David Lillicrap   +3 more
doaj   +2 more sources